Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS
Content archived on 2024-05-24

European development of orphan drugs

Objective

Orphan diseases are defined as disabling or life-threatening diseases, which incidence is below 5 p.10,000people. Some orphan drugs have been developed, mostly in the USA, thanks to the Orphan Drug Act. However, many of them have forsaken because of their low profitability and are still manufactured locally with regulatory status EDOD (European Development of Orphan Drugs) program intends to bring to the market orphan drugs with high medical need which have been forsaken by US firms. These drugs will be selected among products currently locally produced by Hospital Pharmacies and which fall within one the following therapeutic areas: clinical toxicology (antidotes), metabolic diseases or on co-haematology. EDOD aims at upgrading pharmaceutical and medical quality of these medications, and at harmonising at the European level access to these drugs by patients suffering from rare diseases. EDOD will bring together skills from 6 to 8 European SME's, so as to prepare European regulatory filing of 1 to2 drug candidates within 2 years. This will be the start of a longer co-operation between SME's on orphan drugs.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

Data not available

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

EAW - Exploratory awards

Coordinator

OPI - ORPHAN PHARMA INTERNATIONAL
EU contribution
No data
Address
5 allée de la croix des Roux
69126 VAULX EN VELIN
France

See on map

Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (1)

My booklet 0 0